ILMN
Illumina, Inc. · Healthcare · Diagnostics & Research
TECHStrong BuyZACKSBuy
R500#39 today
$273.04
+2.75% today · +1.13% 1W
Oct 2 close or latest
PreviewWhy it's moving
Outperforming without a clear catalyst yet
- ILMN +2.75% on the last session vs SPY +0.74%: +2.0 pts of stock-specific move.
- Aftermath, rsi overbought (Oct 2): After its 11 overbought readings in the past 5 years, ILMN typically gained 3.2% over the next month (median) and was higher 64% of the time; half the outcomes fell between -1.7% and +10.8%. An ordinary month: -0.1%. Among S&P 500 stocks after overbought readings, that ranks #117 of 501.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Key facts
- Market cap
- $41.2B
- Held by institutions
- 106.3%
- Short interest
- 11.5%
- 52-week range
- 88.00–280.17
- Analyst mean target
- —
- Next earnings
- Oct 29 est.
- Forward P/E
- 44.7
Recent events
Earnings ▲
2Q2026 results: EPS $1.31 vs $1.23 expected beat +$0.08 (+6.8%); revenue $1.2B; next session 0.0% (-0.7 vs SPY)Earnings ▲
1Q2026 results: EPS $1.15 vs $1.05 expected beat +$0.10 (+9.0%); revenue $1.1B; next session +7.1% (+6.8 vs SPY)Earnings ▲
4Q2025 results: EPS $1.35 vs $1.23 expected beat +$0.12 (+9.7%); revenue $1.2B; next session -10.4% (-12.3 vs SPY)Earnings ▲
3Q2025 results: EPS $1.34 vs $1.17 expected beat +$0.17 (+14.7%); revenue $1.1B; next session +24.8% (+24.4 vs SPY)